Publications

Found 53 results
Filters: Keyword is HIV Infections  [Clear All Filters]
2017
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD et al..  2017.  HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection.. J Virol. 91(7):e02477-16.
Alsahafi N, Richard J, Prévost J, Coutu M, Brassard N, Parsons MS, Kaufmann DE, Brockman M, Finzi A.  2017.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.. J Virol. 91(16):pii:e00109-17.
Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T et al..  2017.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.. J Virol. 91(7)
Aroh C, Wang Z, Dobbs N, Luo M, Chen Z, Gao J, Yan N.  2017.  Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1.. J Immunol. 199(11):3840-3848.
Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Massanella M, Brassard N, Alsahafi N, Routy J-P, Finzi A et al..  2017.  Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique.. Nat Protoc. 12(10):2029-2049.
Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D et al..  2017.  Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.. J Virol. 91(20)
Martins MA, Shin YC, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Castro I, Magnani DM, Ricciardi M, Pedreño-Lopez N et al..  2017.  Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.. PLoS Pathog. 13(7):e1006529.
2012
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E et al..  2012.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.. N Engl J Med. 367(5):399-410.
Feinberg MB, Ahmed R.  2012.  Born this way? Understanding the immunological basis of effective HIV control. Nat Immunol. 13(7):632-4.
Burton DR, Poignard P, Stanfield RL, Wilson IA.  2012.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.. Science. 337(6091):183-6.
Kwon DS, Angin M, Hongo TC, Law KM, Johnson J, Porichis F, Hart MG, Pavlik DF, Tighe DP, Kavanagh DG et al..  2012.  CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes.. J Virol. 86(12):6586-94.
Klatt NR, Silvestri G.  2012.  CD4+ T cells and HIV: A paradoxical Pas de Deux.. Sci Transl Med. 4(123):123ps4.
Cheng C, Wang L, Wang LS, Gall JGD, Nason M, Schwartz RM, McElrath JM, DeRosa SC, Hural J, Corey L et al..  2012.  Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.. PLoS One. 7(4):e33969.
Walker BD.  2012.  "Elite controllers" provide clues to keeping HIV infection in check. Interview by Tracy Hampton.. JAMA. 308(4):328-9.
Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P et al..  2012.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.. Proc Natl Acad Sci U S A. 109(46):18921-5.
Haynes BF, Gilbert PB, McElrath JM, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. N Engl J Med. 366(14):1275-86.

Pages